Sleep Center, Department of Neurology, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea.
Sleep Med. 2010 Oct;11(9):862-9. doi: 10.1016/j.sleep.2010.07.003.
To investigate the effect of modafinil on cortical excitability in patients with narcolepsy using transcranial magnetic stimulation (TMS).
Nineteen drug-naïve narcolepsy patients with cataplexy (10 males, 9 females, and mean age 28.5 years) and 25 age- and sex-matched healthy controls were recruited. In this double-blind, randomized, crossover study, patients and controls received a single dose of 400mg modafinil or placebo. Modafinil and placebo administrations were separated by a 2-week washout period. TMS parameters, such as resting motor thresholds (RMT), motor-evoked potential (MEP) amplitudes, cortical silent periods (CSP), short-interval intracortical inhibition (SICI), and intracortical facilitation (ICF), were measured before and 3h after administering modafinil or placebo. The differences of TMS parameters were statistically tested between patients and controls and between before and after modafinil or placebo administration.
Narcolepsy patients had significantly increased CSP durations compared to controls (independent t-test, P<0.05), indicating decreased excitability of cortical networks in human narcolepsy. In patients after modafinil administration, MEP amplitudes, SICI, and ICF increased, and CSP duration shortened significantly, meaning enhanced motor excitability, whereas in controls modafinil did not change TMS parameters significantly. Placebo administration did not affect TMS parameters both in patients or controls.
Narcolepsy patients with cataplexy showed decreased cortical excitability than normal healthy controls. Single dose modafinil significantly increased motor excitability in narcolepsy patients but had no effect in healthy controls.
使用经颅磁刺激(TMS)研究莫达非尼对发作性睡病患者皮质兴奋性的影响。
招募了 19 名未经药物治疗的伴有猝倒症的发作性睡病患者(男性 10 名,女性 9 名,平均年龄 28.5 岁)和 25 名年龄和性别匹配的健康对照者。在这项双盲、随机、交叉研究中,患者和对照者接受了单剂量 400mg 莫达非尼或安慰剂。莫达非尼和安慰剂给药之间间隔 2 周洗脱期。在给予莫达非尼或安慰剂之前和之后 3 小时测量 TMS 参数,如静息运动阈值(RMT)、运动诱发电位(MEP)幅度、皮质沉默期(CSP)、短间隔皮质内抑制(SICI)和皮质内易化(ICF)。在患者和对照组之间以及在莫达非尼或安慰剂给药前后,对 TMS 参数的差异进行了统计学检验。
与对照组相比,发作性睡病患者的 CSP 持续时间明显延长(独立 t 检验,P<0.05),表明人类发作性睡病皮质网络兴奋性降低。在莫达非尼给药后,患者的 MEP 幅度、SICI 和 ICF 增加,CSP 持续时间明显缩短,表明运动兴奋性增强,而对照组莫达非尼对 TMS 参数无明显影响。在患者或对照组中,安慰剂给药均不影响 TMS 参数。
伴有猝倒症的发作性睡病患者皮质兴奋性低于正常健康对照组。单次剂量莫达非尼可显著增加发作性睡病患者的运动兴奋性,但对健康对照者无影响。